850 related articles for article (PubMed ID: 31340702)
1. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
[TBL] [Abstract][Full Text] [Related]
2. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
[TBL] [Abstract][Full Text] [Related]
3. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
Kim JH; Kim IW; Kim YW; Park DC; Kim YW; Lee KH; Ahn TG; Han SJ; Ahn WS
Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
[TBL] [Abstract][Full Text] [Related]
4. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer.
Costa S; Sideri M; Syrjänen K; Terzano P; De Nuzzo M; De Simone P; Cristiani P; Finarelli AC; Bovicelli A; Zamparelli A; Bovicelli L
Acta Cytol; 2000; 44(3):310-8. PubMed ID: 10833984
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
6. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
Syrjänen K; Naud P; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Matos J; Gontijo R; Sarian L; Braganca J; Arlindo FC; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S
Anticancer Res; 2005; 25(5):3469-80. PubMed ID: 16101165
[TBL] [Abstract][Full Text] [Related]
7. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
8. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.
Longatto-Filho A; Naud P; Derchain SF; Roteli-Martins C; Tatti S; Hammes LS; Sarian LO; Eržen M; Branca M; de Matos JC; Gontijo R; Maeda MY; Lima T; Costa S; Syrjänen S; Syrjänen K
Virchows Arch; 2012 Jun; 460(6):577-85. PubMed ID: 22562132
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
11. Human papilloma virus infection of uterine cervix and spectrum of cervical pathology in human immunodeficiency virus/AIDS.
Jain BB; Adhikary T; Sadhukhan PC; Nandi A
J Cancer Res Ther; 2021; 17(6):1462-1467. PubMed ID: 34916378
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.
Bansal M; Zhao C
J Low Genit Tract Dis; 2011 Apr; 15(2):105-9. PubMed ID: 21317806
[TBL] [Abstract][Full Text] [Related]
13. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among latin american women <35 and > or =35 years of age: experience from the Latin American Screening Study.
Syrjänen K; Derchain S; Roteli-Martins C; Longatto-Filho A; Hammes LS; Sarian L;
Acta Cytol; 2008; 52(6):641-53. PubMed ID: 19068666
[TBL] [Abstract][Full Text] [Related]
14. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
16. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
17. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
19. Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia.
Njue JK; Muturi M; Kamau L; Lwembe R
Biomed Res Int; 2022; 2022():1930102. PubMed ID: 36164451
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]